Fig. 1: Mutation landscape of the studied cancers.

a Tumor mutation burden of all single base substitutions (SBS; left panel), double base substitutions (CC > TT; middle panel) per group and a proportion of CC > TT DBS relative to C > T SBS in pyrimidine context (right panel). All the cancer types were combined together per XP group. P-values from nonparametric ANOVA are indicated (Kruskal-Wallis test for global P-value estimation and Mann–Whitney U test, two-sided for individual groups P-values). Boxes depict the interquartile range (25–75% percentile), lines—the median, whiskers—1.5× the IQR below the first quartile and above the third quartile. Source data are provided as a Source Data file. b Trinucleotide-context mutation profiles of SBS (left panel) and tetranucleotide-context mutation profiles of CC > TT DBS (right panel) per group. Data are presented as mean values +/− SEM. c Multidimensional scaling (MDS) plot based on the Cosine similarity distance between the SBS trinucleotide-context mutation profiles of the samples. d MDS plot based on the Cosine similarity distance between the trinucleotide-context mutation profiles of the samples using only C > T mutations with an adjacent pyrimidine (YC > YT or CY > TY), the typical UV mutation context. e MDS plot based on the Cosine similarity distance between the tetranucleotide-context mutation profiles of the samples using only CC > TT double base substitutions. f Mean Cosine dissimilarity (1-Cosine distance) between original and reconstructed trinucleotide-context mutation profiles using only SBS7a/b/c/d COSMIC mutation signatures for all SBS (upper panel) and C > T mutations with adjacent pyrimidine only (lower panel). Data are presented as mean values +/− SEM. Source data are provided as a Source Data file. Sample size for all the panels (tumors): n = 31 for SCC, n = 8 for BCC, n = 113 for MEL, n = 10 for XP-E, n = 8 for XP-C, n = 3 for XP-A, n = 3 for XP-D and n = 14 for XP-V.